Arkolith/Insider Trading/LXEO/Form 4

Townsend Richard Nolan

Chief Executive Officer, DirectorLexeo Therapeutics, Inc. (LXEO) · full profile →Form 4 · filed Nov 13, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$20K
Net Open-Market Flow
-$20K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 11, 2024Sell(S)3K$7.82$20K121K
Nov 11, 2024Option exercise(M)3K$2.33$6K123K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 11, 2024Option exercise(M)3K—$0121K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-026737) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Lexeo Therapeutics, Inc.

Build

Ask your agent about LXEO insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001415889-24-026737"
Ask your agent
Use Arkolith to summarize insider buying and selling at Lexeo Therapeutics, Inc.
over the last 90 days and cite the filings.